The study evaluated treatment of about 300 patients who had severe chronic heart failure despite traditional treatment. They were studied in three groups, two of which were treated with different doses of levosimendan while one of the groups received standard medication.
The primary endpoints of the study included an assessment of symptoms, the need for hospitalization, and mortality.
The results did not show clear enough significance to meet the primary endpoints.